<DOC>
	<DOCNO>NCT01071512</DOCNO>
	<brief_summary>The long-term objective establish role Tysabri prevent neurological degeneration multiple sclerosis ( MS ) establish powerful efficient new marker neurological degeneration MS . The study intend correlate cognition two instrument measurements-MRI OCT ( optical coherence tomography ) .</brief_summary>
	<brief_title>Tysabri Effects Cognition Neurodegeneration Multiple Sclerosis</brief_title>
	<detailed_description>The specific aim : 1 . To determine effect Tysabri cognition ( memory , think process , etc . ) 2 . To determine effect Tysabri specific MRI marker cognitive dysfunction 3 . To determine effect Tysabri retinal nerve fiber layer thickness ( RNFL ) use optical coherence tomography ( OCT ) , special instrument use ophthalmology</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Nerve Degeneration</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>18 60 year age inclusive Diagnosis relapse remit multiple sclerosis Prior treatment phase , disease activity least 1 documented relapse previous year OR 2 document relapse previous 2 year OR one new MRI lesion ( Gd+ and/or T2 hyperintense ) An Expanded Disability Status Scale ( EDSS ) score 04.5 inclusive Neurologically stable evidence relapse corticosteroid treatment within 30 day prior treatment Never treat Tysabri/natalizumab . Another type MS relapse remit multiple sclerosis ( RRMS ) A history chronic disease immune system MS know immunodeficiency syndrome/immunocompromised A history presence cancer ( except successfully treat basal squamous cell carcinoma skin ) Active systemic bacterial , viral fungal infection , diagnosis AIDS , Hepatitis B , Hepatitis C infection define positive HIV antibody , Hepatitis B surface antigen Hepatitis C antibody test , respectively Have receive live live attenuate vaccine ( include varicellazoster virus Measles ) within last 2 month Have receive total lymphoid irradiation bone marrow transplantation Have treat : corticosteroid adrenocorticotropic hormone ( ACTH ) within last month , IFNÎ² glatiramer acetate within last 3 month , immunosuppressive medication azathioprine methotrexate within last 6 month , immunoglobulin and/or monoclonal antibody ( include natalizumab ) within last 6 month , cladribine , cyclophosphamide mitoxantrone time . Any medically unstable condition progressive neurological disorder , MS , may affect participation study History clinically significant cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal major disease Unable undergo MRI scan , include claustrophobia , pacemaker history hypersensitivity gadoliniumDTPA Have relapse within 30 day prior AND/OR stabilize previous relapse History severe allergic anaphylactic reaction know drug hypersensitivity natalizumab/Tysabri A clinically significant infectious disease , cellulitis , pneumonia , septicemia History progressive multifocal leukoencephalopathy ( PML ) Participation clinical research study evaluate another investigational drug therapy within last 6 month History Tysabri therapy Abnormal screening blood test Females postmenopausal least 1 year , surgically sterile willing practice effective contraception study Nursing mother , pregnant woman , woman plan become pregnant study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>MRI</keyword>
	<keyword>OCT</keyword>
	<keyword>Tysabri</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>cognition</keyword>
</DOC>